NCT03973268View on ClinicalTrials.gov

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
DepressionMajor Depressive DisorderMajor Depression
Interventions
DEVICE

Arm 1, 2, 3 device interventions

MagPro 100 TMS Therapy System

OTHER

Arm 2 Interventions

Placebo

DRUG

Arm 1, 2, 3 drug Interventions

Ketamine

DRUG

Arm 1 and 2 Interventions

Perampanel

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH